{
    "clinical_study": {
        "@rank": "50365", 
        "arm_group": {
            "arm_group_label": "AMG 232", 
            "arm_group_type": "Experimental", 
            "description": "AMG 232 is an anti-cancer agent"
        }, 
        "brief_summary": {
            "textblock": "Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute\n      myeloid leukemia."
        }, 
        "brief_title": "A Phase 1 Study Evaluating AMG 232 in Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Malignancy", 
            "Cancer", 
            "Oncology", 
            "Oncology Patients", 
            "Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women > 18 years old\n\n          -  Pathologically-documented, definitively-diagnosed AML that is relapsed or refractory\n             to standard treatment, for which no standard therapy is available or the subject\n             refuses standard therapy\n\n          -  Ability to take oral medications and willing to record daily adherance to\n             investigational product\n\n          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments\n\n        Exclusion Criteria:\n\n          -  Active infection requiring intravenous (IV) antibiotics\n\n          -  Prior participation in an investigational study (procedure or device) within 21 days\n             of study day 1\n\n          -  Major surgery within 28 days of study day 1\n\n          -  Anti-tumor therapy within 14 days of study day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016729", 
            "org_study_id": "20120234"
        }, 
        "intervention": {
            "arm_group_label": "AMG 232", 
            "description": "Given an an oral tablet in escalating doses.", 
            "intervention_name": "AMG 232", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "AML", 
        "lastchanged_date": "May 26, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the safety and tolerability of AMG 232 by reviewing clinically significant or \u2265 Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.", 
                "measure": "To evaluate the safety and tolerability of AMG 232", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).", 
                "measure": "Characterize the pharmacokinetics of AMG 232 when administered orally.", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.", 
                "measure": "Determine the maximum tolerated dose of AMG 232, if possible.", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016729"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Complete response (CR), complete response with incomplete recovery (CRi), and duration response.", 
            "measure": "Treatment Response", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}